Abstract Fatigue is one of the most disabling symptoms in multiple sclerosis (MS) patients. There is no or only weak correlation between conventional magnetic resonance imaging (MRI) parameters and level of fatigue.
Introduction
Multiple sclerosis associated fatigue is defined as a ''subjective lack of physical or mental energy that is perceived by the individual or caregiver to interfere with usual and desired activities'' [7] . Fatigue is one of the most common symptoms encountered in MS, leading to a severe level of disability and impaired quality of life [13, 15, 20, 21] . Fatigue occurs in all stages of the disease and usually does not correlate with demographic or disease characteristics such as age, gender, disability or disease severity [2, 3, 18, 22, 23, 28, 40] . The pathophysiology of MS-related fatigue is not fully understood and seems to be multifactorial [7] . Functional imaging studies [12, 34, 35] have demonstrated an abnormal recruitment of cortical and subcortical networks in MS patients with fatigue supporting the theory of a central origin. It has been suggested that diffuse wide-spread axonal loss in MS patients might play a role in the pathogenesis of fatigue. However, structural magnetic resonance imaging (MRI) studies have provided conflicting results concerning the relation between fatigue severity and brain pathology [4] . Since the corpus callosum (CC) is the largest and functionally most important interhemispheric connection bundle, commonly affected in MS, we hypothesized an association between CC atrophy and fatigue.
Patients and methods
This is an exploratory observational MS cohort study with the analysis of CC size on brain MRI as measured at two timepoints, at diagnosis and at time of study. The study was approved by the local ethic committee of the Cantonal Hospital St. Gallen, Switzerland.
Patients
We assessed MRI and fatigue in 97 consecutive patients attending our outpatient clinic and fulfilling the following inclusion criteria: age between 18 and 60 years, diagnosis of a relapsing form of MS according to McDonald criteria (revised version 2005 [31] ) and an actual cranial MRI scan (within 3 months before visit). Exclusion criteria are given in Table 1 .
We excluded four patients due to co-medication supposed to have an effect on fatigue, including one patient with zopiclone, one patient with mirtazapine and two patients with amitryptiline. Moreover, we excluded one patient with pure spinal manifestation of disease, and 22 patients because of depressive symptoms. Thus, this analysis included data of 70 MS patients. Disease duration was defined as time since first manifestation of MS. Relapses were defined as the development of new or recurrent neurological symptoms not associated with fever or infection lasting at least 24 h confirmed by a Swiss or German board-certified neurologist. EDSS and fatigue were assessed with a maximum time distance of 1 month.
Fatigue assessment
Fatigue was assessed in all patients using the Fatigue Severity Scale (FSS; see appendix). FSS is a 9-item measure. The patients had to rate the degree of agreement of a given statement on a 7-point ordinal scale ranging from 1 (strongly disagree) to 7 (strongly agree). Scores were calculated by deriving an arithmetic mean. FSS scores of C4 where suggested to be indicative of ''fatigue'' whereas FSS \4 characterizes ''no fatigue'' [21] . Depressive symptoms were assessed by Beck's Depression Inventory [5] .
MRI analysis
All MRI scans were performed in the radiological institute of the Cantonal Hospital St. Gallen (1.5 Tesla Sigma Magnetom Scanner, Siemens AG, Germany) including an axial pre-and post-Gadolinium T1 weighted, sagittal T1 weighted, sagittal fluid attenuated inversion recovery sequence (FLAIR), axial T2 weighted and axial FLAIR sequences. The first MRI represented the MRI at diagnosis. The last MRI was performed within 3 months before fatigue assessment. All MRI scans were analysed by the same examiner (OY). For CC measurement we used the CC index (CCI) on Picture Archiving Communicating System and if on-screen MRIs are not available on hardcopies. CCI is an established linear measurement technique, published elsewhere ( Fig. 1) [11, 41] .
Higher CCI values indicate a higher CC volume. OY was blinded to the clinical data of the patients. Forty-seven MRIs (33.6%) were evaluated by a second rater (SG), on-screen blinded to the results of OY and clinical data. The concordance rate was 0.91. In 38 patients (54.3%) actual MRI were both available on-screen and hardcopies. In these patients, hardcopy MRIs were additionally evaluated by SG who blinded to the results from on-screen measurement with a Medication which could affect fatigue within the last 8 weeks
Fig. 1 Calculation of corpus callosum index (CCI). CCI is calculated as (aa
Lower CCI values indicate a lower CC volume [11] concordance rate of 0.88. T2 and T1 lesion load and contrast enhancement were determined by Swiss or German boardcertified radiologists. The T2 lesion load was dichotomized as \9 T2 lesions or C9 T2 lesions. T1 lesions and contrast enhancing lesions were categorized as present or absent.
Statistical analysis
Demographic data are presented as mean, standard deviation and 95% confidence interval (CI). Curtosis was calculated for continued variables. We used the Mann-Whitney U test for independent samples for comparison of continued variables and applied the non-parametric rank correlation analysis Spearman-Rho. The significance level was corrected for multiple testings by Bonferroni (adjusted p value: 0.05/5 = 0.01). We used a multivariate linear regression analysis (backward directed regression model) to analyse the interdependence of potential confounding variables. FSS was set as continuous outcome parameter. Clinically meaningful confounders included disease duration, gender, EDSS, age, CCI and annualized CCI change since diagnosis of MS. We used SPSS (MAC version 18; SPSS, Chicago, IL) for all statistical analysis.
Results
Mean FSS in all patients was 3.37 ± 1.88. Forty percent of the patients (n = 28) had fatigue according to the definition (mean FSS score of 5.27 ± 1.1). Sixty percent of the patients (n = 42) had no fatigue (mean FSS score of 2.1 ± 1.0). Patients' demographic and clinical characteristics in total and group-wise are given in Table 2 .
Group-wise univariate comparisons of baseline characteristics
Most of the patients' characteristics were similar in both groups including gender, age, disease duration, annualized relapse and steroid treatment rate, treatment with disease modifying drugs and conventional MRI characteristics. However, patients with fatigue had higher EDSS scores (p = 0.01; Table 2 ).
CC atrophy in patients with and without fatigue
In all patients, mean CCI at diagnosis was 0.36 and decreased to 0.31 in the last MRI (annual CCI decrease -0.8%). CCI values on first and last MRI with refer to time since first manifestation of MS are given in Fig. 2 . CCI at diagnosis and CCI on last MRI were not significantly different in both groups but CCI change over mean of 4.8 years was more pronounced in patients with fatigue: -21.8% compared to those without -12.1% (p = 0.005; Fig. 3a) . This difference remains significant after correction for the time between first and last MRIs: annual CCI decrease was -1.1% in patients with fatigue compared to 0.6% in patients without (p = 0.02). Results of CCI assessment are given in Table 3 .
Correlation analysis between CCI and fatigue CCI change over time correlated with FSS at last MRI (q = -0.333; p = 0.009; Fig. 3b) , EDSS (q = -0.367; p = 0.007) and disease duration (q = -0.378; p = 0.003). Moreover, EDSS correlated with FSS at study time-point (q = 0.361; p = 0.008) and with disease duration (q = 0.489; p \ 0.001). FSS did not correlate with disease duration (q = 0.121; p = 0.34).
Linear regression model
Multivariate linear regression analysis using FSS as the dependent continuous variable and disease duration, gender, EDSS, age, last CCI and annualized CCI (aCCI) change from first to last MRI as co-variates revealed both EDSS and annualized CCI change as independent factors associated with FSS (p value of the regression model = 0.006; adjusted Nagelkerkes' R square = 0.23; Table 4 ).
Discussion
The main finding of our study is that progression of CC atrophy over a mean of 5 years after diagnosis is associated with the occurrence and severity of MS-related fatigue.
In MS patients, CC atrophy is a common finding [17, 38] and correlates with whole brain atrophy [38] . Among others, we recently showed that CC atrophy correlates with progression of disability in MS [29, 36, 41] . In recent decades, several studies could demonstrate cognitive dysfunction in patients with CC abnormalities not only due to MS [11, 26, 32] . In our study, CC atrophied by a mean of approximately 0.8% per year which was in the range of studies using other methods, such as brain parenchymal fraction method (0.5-1.8% annual brain volume loss [1, 6, 16, 19] ). Like in our study, Martola et al. [25] did not find any association between midsagittal CC area and gender, age and disease duration investigating 37 MS patients. That fatigue severity is independent from disease duration is well-known. There are studies reporting a fatigue prevalence of more than 50% in patients with early forms of MS [37] . The association between progression of CC atrophy and fatigue severity in our study was independent from disability. The common scientific viewpoint is that EDSS does not correlate with fatigue despite of some studies which found a weak association [14, 30] . However, the weak correlation between EDSS and fatigue in our study is probably due to patient selection. In the last decade several studies were conducted investigating the association between fatigue and brain pathology. Most of these studies are designed cross-sectional and found, similar to our results, no correlation between fatigue severity and conventional MRI parameters such as the extent and location of T2 lesions [2, 8, 9, 27, 37, 39, 40] , the occurrence of contrast enhancing lesions [23] or brain atrophy [2, 40] . Only one study could demonstrate higher T2 lesion burden in 15 non-disabled MS patients with fatigue compared to 15 patients without [10] with a correlation coefficient of 0.5 (p \ 0.005). Recently, a study found in 24 patients with RRMS and 14 healthy controls reduced grey matter volume in the frontal lobe [33] .
Results from our regression model suggest that progression of corpus callosum atrophy contributes independently to fatigue severity in MS patients. Similar findings were found in another study investigating the association between progression of brain atrophy and fatigue severity: Marrie et al. [24] investigated 134 MS patients and found that an increase of fatigue correlated with changes of brain volume over 8 years while short term changes in brain volume and fatigue were not correlated. In contrast to our study, fatigue was measured by the Sickness Impact Profile Sleep and Rest Scale. They also found that the association between progression of brain atrophy and fatigue was independent from conventional MRI parameters such as contrast enhancement and T2 lesion load. [11, 41] . It has been shown to correlate with brain parenchymal fraction [11] . The concordance rate between two independent raters and between measurement on screen and hardcopies was excellent and similar to results published recently [41] . An advantage of this study is the inclusion of a large community-based patient population, close timing of MRI and fatigue assessment and careful selection criteria to insure the measurement of MS-related fatigue. We excluded patients with progressive forms of MS to avoid a heterogeneous study population with a small number of patients in one group. We used a validated depression scale to exclude patients with depressive symptoms [5] and used FSS because of its high reliability, validity and internal consistency. FSS is the most widely used fatigue scale in cross-sectional and longitudinal MS studies [22] ; initial studies of the FSS to assess test-retest reliability of the FSS in MS provided a correlation coefficient of 0.84. The internal consistency of the FSS using Cronbach in MS was 0.81 [21] . However, FSS remains a subjective parameter. Another disadvantage of this study is the relatively imprecise assessment of disease burden on MRI. Further studies should include exact volumetric measurements of MS lesions.
Conclusions
Progression of CC atrophy over time seems to be an independent risk factor of MS related fatigue. However, our multivariate regression model could explain only about one-fourth of the variance of fatigue severity. MS-related fatigue remains largely unpredictable suggesting other important confounder not yet identified.
There is high need of more objective assessment tools for fatigue. Our results should be reproduced by further studies using innovative quantitative MR-based techniques such as voxel-based morphometry or diffusion tensor imaging.
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